Related Experiment Video

Updated: Aug 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Tyrosine kinase inhibitors in renal cell carcinoma

Anil Potti1, Daniel J George

  • 1Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 28, 2004
PubMed

Insights

New therapies targeting the von Hippel-Lindau (VHL) gene and hypoxia-inducible factor signaling are needed for metastatic kidney cancer. These genetic insights offer potential for novel growth factor-targeted treatments.

Area of Science:

  • Oncology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Metastatic (stage IV) renal cell carcinoma (RCC) treatments, including surgery and immunotherapy (interleukin 2, IFN-alpha), show limited efficacy.
  • Current therapies result in a median progression time of 2-4 months and overall survival of 6-17 months.
  • Standard chemotherapy is ineffective for advanced RCC.

Purpose of the Study:

  • To review potential growth factor targets in clear cell RCC.
  • To explore the relationship between the von Hippel-Lindau (VHL) gene, hypoxia-inducible factor (HIF) signaling, and RCC development.
  • To discuss clinical challenges in developing novel targeted therapies for advanced RCC.

Main Methods:

  • Literature review focusing on VHL gene function in RCC.
  • Analysis of hypoxia-inducible factor signaling pathways in clear cell carcinoma.
  • Examination of emerging growth factor-targeted therapeutic strategies.

Main Results:

  • The von Hippel-Lindau (VHL) gene is a critical tumor suppressor in clear cell RCC.
  • Dysregulation of VHL leads to aberrant hypoxia-inducible factor (HIF) signaling.
  • This pathway presents a genetic basis for targeted therapies.

Conclusions:

  • Understanding VHL and HIF signaling is crucial for developing effective treatments for metastatic RCC.
  • Targeting specific growth factors offers a promising avenue for novel therapeutic strategies.
  • Overcoming clinical challenges is essential for translating these findings into patient benefit.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: